Download Files:
Cabozantinib-d6
$680 – $5,600
Products Details
Product Description
– Cabozantinib-d6 is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].
Web ID
– HY-13016S
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H18D6FN3O5
References
– [1]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.|[2]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.|[3]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
CAS Number
– 1802168-46-2
Molecular Weight
– 507.54
Compound Purity
– 98.14
SMILES
– C(NC1=CC=C(OC=2C3=C(C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C3)N=CC2)C=C1)(=O)C4(C(NC5=CC=C(F)C=C5)=O)CC4
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 120 mg/mL (ultrasonic)
Target
– Apoptosis;c-Kit;c-Met/HGFR;FLT3;TAM Receptor;VEGFR
Pathway
– Apoptosis;Protein Tyrosine Kinase/RTK
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
